Cytosorbents Stock Price, News & Analysis (NASDAQ:CTSO)

$6.68 -0.07 (-1.04 %)
(As of 12/11/2017 06:00 AM ET)
Previous Close$6.75
Today's Range$6.60 - $6.85
52-Week Range$3.30 - $7.05
Volume48,300 shs
Average Volume131,880 shs
Market Capitalization$191.51 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.53

About Cytosorbents (NASDAQ:CTSO)

Cytosorbents logoCytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885

Debt

Debt-to-Equity Ratio0.73%
Current Ratio3.36%
Quick Ratio3.17%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.53 million
Price / Sales20.11
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-334.00

Profitability

Trailing EPS($0.32)
Net Income$-11,930,000.00
Net Margins-67.83%
Return on Equity-233.72%
Return on Assets-57.58%

Miscellaneous

Employees65
Outstanding Shares28,690,000

Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) posted its quarterly earnings results on Tuesday, August, 9th. The medical research company reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.03. The medical research company earned $1.90 million during the quarter, compared to analyst estimates of $2.18 million. Cytosorbents had a negative return on equity of 233.72% and a negative net margin of 67.83%. View Cytosorbents' Earnings History.

When will Cytosorbents make its next earnings announcement?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Friday, March, 2nd 2018. View Earnings Estimates for Cytosorbents.

Where is Cytosorbents' stock going? Where will Cytosorbents' stock price be in 2017?

5 equities research analysts have issued 1-year price objectives for Cytosorbents' stock. Their predictions range from $7.00 to $13.00. On average, they expect Cytosorbents' stock price to reach $10.45 in the next twelve months. View Analyst Ratings for Cytosorbents.

What are Wall Street analysts saying about Cytosorbents stock?

Here are some recent quotes from research analysts about Cytosorbents stock:

  • 1. Maxim Group analysts commented, "CytoSorbents reported 3Q17 with revenue of $3.8M ($3.4M in product sales and $375K in grant income) and spent $5.9M in the quarter for a net loss of $2M. CytoSorb sales continue to rise with 11% sequential growth (61% YoY). The increase in product revenue was driven by an increase in direct sales to both new customers and repeat orders from existing customers, as well as increased sales to distributers. The company did not provide guidance, but reiterated it expects 2H17 sales to exceed 1H17. CytoSorbents ended the period with $15.4M in cash." (11/10/2017)
  • 2. HC Wainwright analysts commented, "CytoSorbents reported full-year 2016 financial results and held a conference call on March 3. The company reported revenues of $9.5M, higher than our estimate of $8.7M, and a net loss of $0.47 per share, compared to our estimated net loss of $0.40 per share. The differences mainly resulted from higher-than-expected product sales, offset by increased R&D and SG&A increases. We have updated our model to reflect the 2016 financial results." (3/6/2017)

Who are some of Cytosorbents' key competitors?

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:

  • Al Kraus, Chairman of the Board (Age 70)
  • Phillip P. Chan M.D., Ph.D., President, Chief Executive Officer, Director (Age 45)
  • Kathleen P. Bloch CPA, Chief Financial Officer (Age 58)
  • Vincent J. Capponi, Chief Operating Officer (Age 55)
  • Eric G. Mortensen, Chief Medical Officer
  • Michael G. Bator, Director
  • James T. Gunton, Independent Director (Age 49)
  • Edward R. Jones M.D., Independent Director (Age 66)
  • Alan D. Sobel, Independent Director (Age 54)

Who owns Cytosorbents stock?

Cytosorbents' stock is owned by a number of of institutional and retail investors. Top institutional investors include Skylands Capital LLC (1.78%), Wealthcare Advisory Partners LLC (0.21%), Fortaleza Asset Management Inc. (0.08%) and Advisor Group Inc. (0.06%). Company insiders that own Cytosorbents stock include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.

Who sold Cytosorbents stock? Who is selling Cytosorbents stock?

Cytosorbents' stock was sold by a variety of institutional investors in the last quarter, including Skylands Capital LLC and Advisor Group Inc.. View Insider Buying and Selling for Cytosorbents.

Who bought Cytosorbents stock? Who is buying Cytosorbents stock?

Cytosorbents' stock was purchased by a variety of institutional investors in the last quarter, including Wealthcare Advisory Partners LLC and Fortaleza Asset Management Inc.. Company insiders that have bought Cytosorbents stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents.

How do I buy Cytosorbents stock?

Shares of Cytosorbents can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of Cytosorbents stock can currently be purchased for approximately $6.68.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $191.51 million and generates $9.53 million in revenue each year. The medical research company earns $-11,930,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 65 workers across the globe.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]


MarketBeat Community Rating for Cytosorbents (CTSO)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytosorbents (NASDAQ:CTSO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.71$12.71$12.71$12.38
Price Target Upside: 95.51% upside103.23% upside176.27% upside213.29% upside

Cytosorbents (NASDAQ:CTSO) Consensus Price Target History

Price Target History for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightReiterated RatingBuy$13.00N/AView Rating Details
11/10/2017B. RileyReiterated RatingBuy$11.25N/AView Rating Details
11/10/2017Maxim GroupReiterated RatingBuy$12.00N/AView Rating Details
7/25/2017AegisReiterated RatingBuy$9.00HighView Rating Details
6/7/2017CowenInitiated CoverageOutperform$7.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$24.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Cytosorbents (NASDAQ:CTSO) Earnings History and Estimates Chart

Earnings by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ CTSO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.10)N/AView Earnings Details
8/7/2017Q2 2017($0.06)($0.04)$3.29 million$3.57 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.11)($0.05)$2.99 million$3.11 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.10)($0.16)$2.59 million$3.08 millionViewN/AView Earnings Details
11/7/2016Q3($0.11)($0.11)$2.35 million$2.14 millionViewListenView Earnings Details
8/9/2016Q216($0.09)($0.12)$2.18 million$1.90 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.08)$1.73 million$1.80 millionViewN/AView Earnings Details
3/9/2016Q415($0.08)($0.08)$1.51 million$1.76 millionViewN/AView Earnings Details
11/13/2015Q315($0.10)($0.11)$1.26 million$1.30 millionViewListenView Earnings Details
8/13/2015Q215($0.11)$0.05$0.92 million$0.96 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.11)$0.80 million$0.72 millionViewListenView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.13 million$1.03 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cytosorbents (NASDAQ:CTSO) Earnings Estimates

2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.11)($0.11)($0.11)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.08)($0.07)($0.08)
Q4 20172($0.09)($0.08)($0.09)
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytosorbents (NASDAQ:CTSO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cytosorbents (NASDAQ CTSO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 8.65%
Insider Trades by Quarter for Cytosorbents (NASDAQ:CTSO)
Institutional Ownership by Quarter for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ CTSO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/27/2017Vincent CapponiCOOSell4,000$7.00$28,000.00View SEC Filing  
6/9/2017Eric R MortensenInsiderBuy2,500$4.04$10,100.00View SEC Filing  
6/9/2017Michael G. BatorDirectorBuy1,500$4.12$6,180.00View SEC Filing  
6/8/2017Phillip P. ChanInsiderBuy3,700$4.00$14,800.00View SEC Filing  
6/8/2017Vincent CapponiCOOBuy2,500$4.00$10,000.00View SEC Filing  
6/5/2017Phillip P. ChanInsiderBuy6,300$4.00$25,200.00View SEC Filing  
5/15/2017Kathleen P. BlochCFOBuy1,000$4.34$4,340.00View SEC Filing  
12/9/2016Phillip P. ChanInsiderBuy4,600$5.40$24,840.00View SEC Filing  
12/6/2016Kathleen P BlochCFOBuy1,000$4.83$4,830.00View SEC Filing  
8/24/2016Phillip P ChanInsiderBuy5,000$4.89$24,450.00View SEC Filing  
6/7/2016Michael G BatorDirectorBuy3,000$4.88$14,640.00View SEC Filing  
10/29/2015Vincent CapponiCOOSell4,000$7.50$30,000.00View SEC Filing  
10/15/2015Al KrausDirectorSell6,774$6.22$42,134.28View SEC Filing  
10/8/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
10/1/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
9/24/2015Al KrausDirectorSell10,000$6.44$64,400.00View SEC Filing  
9/17/2015Al KrausDirectorSell10,000$6.64$66,400.00View SEC Filing  
9/10/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
9/3/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/27/2015Al KrausDirectorSell10,000$6.39$63,900.00View SEC Filing  
8/20/2015Al KrausDirectorSell10,000$7.26$72,600.00View SEC Filing  
8/13/2015Al KrausDirectorSell10,000$6.26$62,600.00View SEC Filing  
7/23/2015Al KrausDirectorSell10,000$6.28$62,800.00View SEC Filing  
7/16/2015Al KrausDirectorSell10,000$6.33$63,300.00View SEC Filing  
7/9/2015Al KrausDirectorSell10,000$5.98$59,800.00View SEC Filing  
7/2/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/25/2015Al KrausDirectorSell13,205$7.33$96,792.65View SEC Filing  
6/18/2015Al KrausDirectorSell10,000$5.78$57,800.00View SEC Filing  
6/11/2015Al KrausDirectorSell10,000$6.29$62,900.00View SEC Filing  
6/4/2015Al KrausDirectorSell10,000$6.30$63,000.00View SEC Filing  
5/28/2015Al KrausDirectorSell10,000$6.32$63,200.00View SEC Filing  
11/17/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/10/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
11/3/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
10/27/2014Al KrausDirectorSell100,000$0.24$24,000.00View SEC Filing  
10/10/2014James T GuntonDirectorSell1,240,762$0.24$297,782.88View SEC Filing  
10/6/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/29/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/25/2014Al KrausDirectorSell41,500$0.23$9,545.00View SEC Filing  
9/22/2014Al KrausDirectorSell8,500$0.23$1,955.00View SEC Filing  
9/15/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/12/2014James T GuntonDirectorSell30,450$0.24$7,308.00View SEC Filing  
9/8/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
9/5/2014James T GuntonDirectorSell100,000$0.24$24,000.00View SEC Filing  
9/2/2014Al KrausDirectorSell50,000$0.25$12,500.00View SEC Filing  
9/2/2014Kathleen P BlochCFOBuy65,000$0.23$14,950.00View SEC Filing  
8/28/2014James T GuntonDirectorSell214,387$0.24$51,452.88View SEC Filing  
8/27/2014James T GuntonDirectorSell1,360,000$0.24$326,400.00View SEC Filing  
8/25/2014Al KrausDirectorSell100,000$0.25$25,000.00View SEC Filing  
8/18/2014Al KrausDirectorSell100,000$0.27$27,000.00View SEC Filing  
8/11/2014Al KrausDirectorSell100,000$0.28$28,000.00View SEC Filing  
8/4/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/21/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/10/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
7/7/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
6/23/2014Al KrausDirectorSell50,000$0.23$11,500.00View SEC Filing  
6/18/2014Al KrausDirectorSell50,000$0.24$12,000.00View SEC Filing  
5/20/2014Kathleen P BlochCFOBuy110,000$0.24$26,400.00View SEC Filing  
9/4/2012Phillip P ChanCEOBuy190,000$0.13$24,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytosorbents (NASDAQ CTSO) News Headlines

Source:
DateHeadline
 Analysts Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $4.23 Million Analysts Anticipate Cytosorbents Corp (CTSO) Will Post Quarterly Sales of $4.23 Million
www.americanbankingnews.com - December 11 at 4:04 AM
Insider Selling: Cytosorbents Corp (CTSO) COO Sells 4,000 Shares of StockInsider Selling: Cytosorbents Corp (CTSO) COO Sells 4,000 Shares of Stock
www.americanbankingnews.com - December 8 at 6:22 PM
ETFs with exposure to CytoSorbents Corp. : December 8, 2017ETFs with exposure to CytoSorbents Corp. : December 8, 2017
finance.yahoo.com - December 8 at 5:03 PM
Cytosorbents Corp (CTSO) Receives Consensus Rating of "Buy" from AnalystsCytosorbents Corp (CTSO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 4:57 AM
Is Cytosorbents Corporation’s (CTSO) Balance Sheet Strong Enough To Weather A Storm?Is Cytosorbents Corporation’s (CTSO) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 24 at 11:00 AM
FY2018 EPS Estimates for Cytosorbents Corporation (CTSO) Cut by AnalystFY2018 EPS Estimates for Cytosorbents Corporation (CTSO) Cut by Analyst
www.americanbankingnews.com - November 23 at 4:30 PM
$4.25 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter$4.25 Million in Sales Expected for Cytosorbents Corporation (CTSO) This Quarter
www.americanbankingnews.com - November 23 at 6:32 AM
CTSO: Germany Reimbursement Rebounds, Drives Strong Record ProductCTSO: Germany Reimbursement Rebounds, Drives Strong Record Product
finance.yahoo.com - November 21 at 5:48 PM
HC Wainwright Reaffirms "Buy" Rating for Cytosorbents Corporation (CTSO)HC Wainwright Reaffirms "Buy" Rating for Cytosorbents Corporation (CTSO)
www.americanbankingnews.com - November 21 at 4:41 PM
Cytosorbents Corporation (CTSO) to Post Q1 2018 Earnings of ($0.10) Per Share, B. Riley ForecastsCytosorbents Corporation (CTSO) to Post Q1 2018 Earnings of ($0.10) Per Share, B. Riley Forecasts
www.americanbankingnews.com - November 13 at 6:00 AM
Cytosorbents Corporation (CTSO) Rating Reiterated by B. RileyCytosorbents Corporation (CTSO) Rating Reiterated by B. Riley
www.americanbankingnews.com - November 12 at 8:38 AM
CytoSorbents Recognized on Deloittes 2017 Technology Fast 500™ as One of the Fastest Growing Companies in ... - PR Newswire (press release)CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in ... - PR Newswire (press release)
www.prnewswire.com - November 11 at 10:46 AM
Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results - Earnings Call TranscriptCytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 5:31 PM
Cytosorbents Corporation (CTSO) Given "Buy" Rating at Maxim GroupCytosorbents Corporation (CTSO) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - November 10 at 10:24 AM
CytoSorbents Recognized on Deloittes 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North AmericaCytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America
finance.yahoo.com - November 10 at 7:02 AM
ETFs with exposure to CytoSorbents Corp. : November 9, 2017ETFs with exposure to CytoSorbents Corp. : November 9, 2017
finance.yahoo.com - November 10 at 7:02 AM
CytoSorbents Corporation to Host Earnings CallCytoSorbents Corporation to Host Earnings Call
finance.yahoo.com - November 10 at 7:02 AM
CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017
finance.yahoo.com - November 10 at 7:02 AM
CytoSorbents reports 3Q lossCytoSorbents reports 3Q loss
finance.yahoo.com - November 10 at 7:02 AM
Cytosorbents Corporation (CTSO) Expected to Post FY2020 Earnings of $0.30 Per ShareCytosorbents Corporation (CTSO) Expected to Post FY2020 Earnings of $0.30 Per Share
www.americanbankingnews.com - November 8 at 10:44 PM
Cytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by BrokeragesCytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 6 at 1:40 AM
CytoSorbents to Report Q3 2017 Operating and Financial ResultsCytoSorbents to Report Q3 2017 Operating and Financial Results
finance.yahoo.com - November 2 at 6:35 PM
CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe HyperkalemiaCytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia
finance.yahoo.com - November 1 at 6:35 PM
-$0.08 EPS Expected for Cytosorbents Corporation (CTSO) This Quarter-$0.08 EPS Expected for Cytosorbents Corporation (CTSO) This Quarter
www.americanbankingnews.com - November 1 at 1:54 PM
ETFs with exposure to CytoSorbents Corp. : October 30, 2017ETFs with exposure to CytoSorbents Corp. : October 30, 2017
finance.yahoo.com - October 30 at 6:11 PM
Cytosorbents Corporation (CTSO) Set to Announce Earnings on MondayCytosorbents Corporation (CTSO) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 9:14 AM
CTSO: Additional Evidence Supporting CytoSorb Use in Sepsis, Cardiac SurgeryCTSO: Additional Evidence Supporting CytoSorb Use in Sepsis, Cardiac Surgery
finance.yahoo.com - October 28 at 12:20 AM
ETFs with exposure to CytoSorbents Corp. : October 20, 2017ETFs with exposure to CytoSorbents Corp. : October 20, 2017
finance.yahoo.com - October 20 at 7:07 PM
CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve SurvivalCytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival
finance.yahoo.com - October 19 at 6:13 PM
Cytosorbents Corporation (CTSO) Given a $12.00 Price Target by Maxim Group AnalystsCytosorbents Corporation (CTSO) Given a $12.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - October 19 at 1:08 PM
Financial Analysis: Waters Corporation (WAT) & Cytosorbents Corporation (CTSO)Financial Analysis: Waters Corporation (WAT) & Cytosorbents Corporation (CTSO)
www.americanbankingnews.com - October 15 at 2:22 PM
Reviewing Cytosorbents Corporation (CTSO) and Its PeersReviewing Cytosorbents Corporation (CTSO) and Its Peers
www.americanbankingnews.com - October 12 at 8:08 PM
CytoSorbents to Present at the 2017 BIO Investor Forum - PR Newswire (press release)CytoSorbents to Present at the 2017 BIO Investor Forum - PR Newswire (press release)
www.prnewswire.com - October 12 at 2:46 AM
Cytosorbents Corporation (CTSO) Receives Consensus Rating of "Buy" from AnalystsCytosorbents Corporation (CTSO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 12 at 2:44 AM
CytoSorbents to Present at the 2017 BIO Investor ForumCytoSorbents to Present at the 2017 BIO Investor Forum
finance.yahoo.com - October 10 at 3:22 PM
ETFs with exposure to CytoSorbents Corp. : October 9, 2017ETFs with exposure to CytoSorbents Corp. : October 9, 2017
finance.yahoo.com - October 9 at 3:14 PM
CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 3:26 PM
CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine CongressCytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress
www.bizjournals.com - September 27 at 6:55 PM
Cytosorbents Corporations (CTSO) Buy Rating Reaffirmed at HC WainwrightCytosorbents Corporation's (CTSO) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 26 at 7:24 AM
Cytosorbents (CTSO) Says Key Clinical Study Shows Reversal of Refractory Septic Shock in Patients Treated with ... - StreetInsider.comCytosorbents (CTSO) Says Key Clinical Study Shows Reversal of Refractory Septic Shock in Patients Treated with ... - StreetInsider.com
www.streetinsider.com - September 25 at 4:06 PM
Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®
finance.yahoo.com - September 25 at 12:11 PM
Comparing Cytosorbents Corporation (CTSO) & Cerner Corporation (CERN)Comparing Cytosorbents Corporation (CTSO) & Cerner Corporation (CERN)
www.americanbankingnews.com - September 24 at 10:08 PM
Cytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by AnalystsCytosorbents Corporation (CTSO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 17 at 2:50 AM
Comparing Cytosorbents Corporation (CTSO) & Its PeersComparing Cytosorbents Corporation (CTSO) & Its Peers
www.americanbankingnews.com - September 15 at 2:14 AM
World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes CeremonyWorld Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony
finance.yahoo.com - September 14 at 6:26 PM
Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ TransplantationAferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation
finance.yahoo.com - September 11 at 6:17 PM
CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference - PR Newswire (press release)CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - September 6 at 5:37 PM
CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment ConferenceCytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference
finance.yahoo.com - September 6 at 5:36 PM
Cytosorbents Corporation (CTSO) Expected to Announce Earnings of -$0.09 Per ShareCytosorbents Corporation (CTSO) Expected to Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - September 6 at 4:26 AM
CytoSorbents Highlights Important Research...CytoSorbents Highlights Important Research...
www.benzinga.com - September 5 at 7:11 PM

SEC Filings

Cytosorbents (NASDAQ:CTSO) SEC Filings

DateFilerForm TypeView
12/08/2017
3:12 PM
Capponi Vincent (Reporting)
Cytosorbents (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Cytosorbents (NASDAQ:CTSO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytosorbents (NASDAQ CTSO) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.